Skip to main
MGTX

MGTX Stock Forecast & Price Target

MGTX Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MeiraGTx Holdings is a promising clinical-stage genetic medicines company with a strategic pipeline that includes treatments for diseases with high unmet need, strong manufacturing capabilities, and proprietary gene therapy platforms. The company's recent data update on its AAV2-hAQP1 gene therapy for radiation-induced xerostomia showed sustained clinical benefit and secured FDA Breakthrough Therapy Designation, providing strong support for its potential approval and commercialization. With the recent reacquisition of its botaretigene sparoparvovec program for X-linked retinitis pigmentosa (XLRP), the company is well-positioned for near-term regulatory progress and commercial launch, supported by a strong balance sheet and potential non-dilutive financing opportunities. However, risks to the outlook include clinical execution, regulatory uncertainties, IP risk, and long-term pricing pressure. Overall, the current pipeline and financial prospects support a positive outlook on MeiraGTx Holdings' stock.

Bears say

MeiraGTx Holdings is a vertically integrated, clinical-stage genetic medicines company operating in a highly competitive and complex market with significant regulatory uncertainties, IP risks, and pricing pressures. Although the company is making progress in aligning with sustainability principles and has a promising pipeline development, it still faces significant risks in clinical program execution, competition, and delays in obtaining regulatory approvals. Therefore, the outlook for the MeiraGTx Holdings stock remains negative in the near term.

MGTX has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MeiraGTx Holdings plc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MeiraGTx Holdings plc (MGTX) Forecast

Analysts have given MGTX a Strong Buy based on their latest research and market trends.

According to 7 analysts, MGTX has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MeiraGTx Holdings plc (MGTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.